896 abstracts found.



Results filter



Models for delivery of follow-up care – what does the evidence tell us thus far?

Year:

Session type:

Jon Emery1

1University of Melbourne, Melbourne, Australia




Optimising care beyond breast cancer – perspectives from the front line

Year:

Session type:

Alastair M Thompson1, Maggie Wilcox2
1University of Texas MD Anderson Cancer Center, Houston, USA,2Independent Cancer Patients' Voice, London, UK



Tumour-propagating cells in non-small cell lung cancer

Year:

Session type:

Carla Kim1
1Children's Hospital Boston, Boston, USA



Neutral and biased replacement of intestinal stem cells

Year:

Session type:

Doug Winton1
1Cancer Research UK Cambridge Institute, Cambridge, UK



Introduction: Cancer evolution

Year:

Session type:

Charles Swanton1,2
1Cancer Research UK London Research Institute, London, UK,2niversity College London Cancer Institute, London, UK



Making sense of intratumour heterogeneity: evidence of a ‘Big Bang’ tumour expansion

Year:

Session type:

Andrea Sottoriva1
1The Institute of Cancer Research, London, UK



Unravelling the complexity of lung cancer evolution

Year:

Session type:

Nicholas McGranahan1
1CR-UK London Research Institute, London, UK



Computational dissection of intratumour genetic heterogeneity and applications to the study of cancer treatment, evolution and metastasis

Year:

Session type:

Scott Carter1,2
1Broad Institute of MIT-Harvard, Cambridge, MA, USA,2Dana-Farber Cancer Institute, Boston, MA, USA,3Massachusetts General Hospital, Boston, MA, USA



What can we learn from circulating tumour cells in lung cancer – biomarkers, mouse models, drug resistance and heterogeneity

Year:

Session type:

Caroline Dive1
1Cancer Research UK Manchester Institute, Manchester, UK



Introduction: Cancer immunotherapy 2014: a new paradigm

Year:

Session type:

James Larkin1
1The Royal Marsden NHS Foundation Trust, London, UK



Introduction: Inflammation and cancer

Year:

Session type:

Fran Balkwill1
1Queen Mary, University of London, London, UK



T cell checkpoint blockade in melanoma: from mouse to man and back

Year:

Session type:

Christian Blank1
1The Netherlands Cancer Institute, Amsterdam, The Netherlands



The targets for tumour immunotherapy mediated by the inflammatory properties of vesicular stomatitis virus (VSV)-based antigen presentation depend upon the tumour’s anatomical site

Year:

Session type:

Richard Vile1
1Mayo Clinic, Rochester, USA



Targeting immune checkpoints in cancer: new mechanistic insights

Year:

Session type:

Sergio A Quezada1
1UCL Cancer Institute, University College London, London, UK



Co-targeting angiogenesis and immunosuppressive cell networks to improve anti-cancer therapy

Year:

Session type:

Michele De Palma1
The Swiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences, Swiss Federal Institute of Technology Lausanne (EPFL), Lausanne, Switzerland (1)



T cell immunosurveillance of healthy and transformed epithelia

Year:

Session type:

Adrian Hayday1
1King's College London, London, UK



Neutrophil-derived signals promote initiation abilities of cancer stem cells during metastasis

Year:

Session type:

Ilaria Malanchi1
1Cancer Research UK, London, UK



Introduction: High precision radiation therapy

Year:

Session type:

Diana Tait1
1The Royal Marsden NHS Foundation Trust and The Royal College of Radiologists, London, UK



Progress in breast cancer prevention

Year:

Session type:

Jack Cuzick1
1Queen Mary, University of London, London, UK



Stereotactic ablative radiotherapy (SABR): a local therapy poised to fight metastatic cancer

Year:

Session type:

Robert Timmerman1
1University of Texas Southwestern Medical Center, Dallas, USA



Effects of aspirin on cancer incidence and metastasis

Year:

Session type:

Peter M Rothwell1
1University of Oxford, Oxford, UK



Proton therapy: pushing the frontiers of radiotherapy

Year:

Session type:

Tony Lomax1
1Centre for Proton Therapy, Paul Scherrer Institut, Villigen, Switzerland



Cancer and obesity prevention: finding the causes of the causes

Year:

Session type:

Tim Lobstein1,2
1World Obesity Federation, London, UK,2Curtin University, Perth, Australia



Image guided radiation therapy

Year:

Session type:

Uwe Oelfke1
1The Institute of Cancer Research UK and The Royal Marsden NHS Foundation Trust, London, UK



Introduction: Stem cells and cancer

Year:

Session type:

Axel Behrens1
1ancer Research UK London Research Institute, London, UK



Introduction: Optimising care for those living with and beyond cancer – where does primary care fit in?

Year:

Session type:

Eila Watson1
1Oxford Brookes University, UK, Oxford, UK



Wnt activating mechanisms in colorectal cancer

Year:

Session type:

Vivian Li1
1Medical Research Council (MRC) National Institute for Medical Research, London, UK



Primary care views on optimising care for those living with and beyond cancer: findings from a systematic review and GP survey

Year:

Session type:

Fiona Walter1
1University of Cambridge, Cambridge, UK

Gremlin1 over-expression causes intestinal tumorigenesis in humans and mice arising from cells outside the crypt base stem cell niche

Year:

Session type:

Ian Tomlinson1
1University of Oxford, Oxfors, UK

BACR Tom Connors lecture – Targeting and imaging cancer phenotypes: Focal Adhesion Kinase as a critical regulator of tumour cells and the host immune response

Year:

Session type:

Margaret Frame1
1Cancer Research UK Edinburgh Centre, University of Edinburgh, Edinburgh, UK

Supportive care in cancer patients: a unifying concept

Year:

Session type:

Jean A Klastersky1
1Institut Jules Bordet - ULB, Brussels, Belgium

From symptom to cancer treatment: the vital clinical and political leadership

Year:

Session type:

Peter Vedsted1
1Aarhus University, Aarhus, Denmark

Liquid biopsies: genotyping circulating tumour cells

Year:

Session type:

David Planchard1
1Gustave Roussy, Paris, France

Cancer genomics: state of the science and clinical translation

Year:

Session type:

Elaine R Mardis1
1The Genome Institute at Washington University School of Medicine, St Louis, USA

Genomics of lung cancer

Year:

Session type:

Ramaswamy Govindan1
1Washington University School of Medicine, St Louis, USA



Introduction: Circulating biomarkers: where have we got to and what’s on the horizon?

Year:

Session type:

Caroline Dive1
1Cancer Research UK, Manchester, UK

Targeting phosphoinositide 3-kinase for cancer therapy

Year:

Session type:

Lewis C Cantley1
1Weill Cornell Medical School, Cornell University, New York, USA



Molecular profiling of single circulating tumour cells with diagnostic intention

Year:

Session type:

Christoph Klein1,2
1University of Regensburg, Regensburg, Germany,2Fraunhofer Project Group, ITEM-Regensburg, Germany

Targeting phosphoinositide 3-kinase for cancer therapy

Year:

Session type:

Lewis C Cantley1
1Weill Cornell Medical School, Cornell University, New York, USA



Circulating cell-free DNA as a strong multimarker diagnostic, theranostic and prognostic tool for metastatic colorectal cancer patients management care

Year:

Session type:

Alain R Thierry1
1French Institute of Health and Medical Research (INSERM), Montpellier, France

Communicating risk and uncertainty to patients and the media

Year:

Session type:

David Spieglehalter1
1University of Cambridge, Cambridge, UK

Genomically-inspired treatment of lymphoma by targeting oncogenic signalling

Year:

Session type:

Louis M Staudt1
1National Cancer Institute, Bethesda, USA

Quantitative oncology: biologically informed and clinically actionable

Year:

Session type:

Peter Kuhn1
1University of Southern California, Los Angeles, USA

Psychiatric aspects of palliative care: meaning and existential issues in end of life care

Year:

Session type:

William Breitbart1
1Memorial Sloan-Kettering Cancer Center, New York, USA

Whither drug discovery: the genetic basis for cancer therapeutics

Year:

Session type:

William R Sellers1
1Novartis Institutes for BioMedical Research, Cambridge, USA

Challenging nuclear fiction: new roles for old nuclear proteins

Year:

Session type:

Ron Laskey1
1University of Cambridge, Cambridge, UK

Mouse models of malignant glioblastoma multiforme: cancer stem cells and beyond

Year:

Session type:

Luis Parada1
1University of Texas Southwestern Medical Center, Dallas, USA

Pan-RAF inhibitor active in melanomas that are resistant to BRAF or BRAF /MEK inhibitor combinations.

Year:

Session type:

Maria Romina Girotti1, Filipa Lopes2, Natasha Preece2, Dan Niculescu-Duvaz2, Alfonso Zambon2, Lawrence Davies2, Steven Whittaker2, Grazia Saturno1, Amaya Viros1, Malin Pedersen4, McLeary Robert2, Johnson Louise2, Fish Laura2, Ejiama Sarah1, Marusiak Anna A3, Fusi Alberto5, John Brognard3, Paul Lorigan5, Caroline Springer2, Richard Marais1
1Molecular Oncology Group - Cancer Research UK Manchester Institute, Manchester, UK,2Gene and Oncogene Targeting Team - The Institute of Cancer Research, London, UK,3Signal Transduction Team - Cancer Research UK Manchester Institute, Manchester, UK,4Targeted Therapy Team - The Institute of Cancer Research, London, UK,5University of Manchester - Christie NHS Foundation Trust, Manchester, UK

Mouse models of malignant glioblastoma multiforme

Year:

Session type:

Luis Parada1

1University of Texas Southwestern Medical Center, Dallas, USA


Drug discovery targets for anti-cancer antibodies

Year:

Session type:

Martin Glennie1
1University of Southampton, Southampton, UK